Artrya (ASX:AYA): 3Q26 cash flow

142 Views30 Apr 2026 16:00

Issuer-paid

SUMMARY

Strong cash position: Artrya reported its 3Q26 cash results.
With commercialisation only really starting during the quarter, income from customers remains low.
- Customer receipts: $46 thousand – timing of receipts pushed cash flow into the June quarter - Operating cost: -$6.8 million – The step up in R&D activity leading up to Salix Coronary Flow (SCF) submission saw R&D costs increase to $1.6m, in line with previous submissions (SCA and SCP) - R&D rebate: $5.6 million – R&D tax rebate.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream